Recce Ltd has released a press release.
Recce Completes 5,000 R327 Doses Per Week under GMP
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Recce Pharmaceuticals - Business Update
- Patent Granted in Israel for RECCE Anti-Infectives
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Recce Receives AUD $11.17m R&D Advance
- Safety Committee Approves Expansion of Ph I/II DFI Trial
Later from Recce Pharmaceuticals
- Safety Committee Approves High Dose of 4,000mg
- China Patent Granted for RECCE Anti-Infectives
- MCRI Pilot Study- Positive Efficacy Data for Lung Infections
- Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
- Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals